Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including ...

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval that ...

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with non-small cell lung cancer across Australia, the United States and Europe.

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit ...

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

If everyone eligible had a lung cancer screening, 62,000 lives would be saved over five years, a new study shows.

In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association. In the US, ...